NCT01620424 - Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

April 30, 2001

Study Completion Date

April 30, 2001

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits

DRUG

biphasic insulin aspart 50

Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo